www.microbialcell.com

An adenine model of inborn metabolism errors alters TDP-43 aggregation and reduces its toxicity in yeast revealing insights into protein misfolding diseases

Sangeun Park, Sei-Kyoung Park, Peter Blair and Susan W. Liebman*

Department of Pharmacology, University of Nevada, Reno, United States of America.

* Corresponding Author.

Susan W. Liebman, Department of Pharmacology, University of Nevada, 1664 N Virginia; Mail stop 318, Reno, NV 89557; Office: 775-682-7338; Lab: 775-327-2251; FAX: 775-784-1419; E-mail: sliebman@unr.edu

ABSTRACT TDP-43 is linked to human diseases such as amyotrophic lateral sclerosis (ALS) and frontotemporal degeneration (FTD). Expression of TDP-43 in yeast is known to be toxic, cause cells to elongate, form liquid-like aggregates, and inhibit autophagy and TOROID formation. Here, we used the apt1∆ aah1∆ yeast model of inborn errors of metabolism, previously shown to lead to intracellular adenine accumulation and adenine amyloid-like fiber formation, to explore interactions with TDP-43. Results show that the double deletion shifts the TDP-43 aggregates from liquid-like droplets toward a more amyloid-like state. At the same time the deletions reduce TDP-43's effects on toxicity, cell morphology, autophagy, and TOROID formation without affecting the level of TDP-43. This suggests that the liquid-like droplets rather than amyloid-like TDP-43 aggregates are responsible for the deleterious effects in yeast. How the apt1∆ aah1∆ deletions alter TDP-43 aggregate formation is not clear. Possibly, it results from adenine and TDP-43 fiber interactions as seen for other heterologous fibers. This work offers new insights into the potential interactions between metabolite-based amyloids and pathological protein aggregates, with broad implications for understanding protein misfolding diseases.

doi: 10.15698/mic2025.05.850 Received originally: 16.10.2024; in revised form: 16.04.2025, Accepted 24.04.2025, Published 22.05.2025.

Keywords: yeast, TDP-43, liquid-like droplets, metabolite-based amyloids, FRAP, metabolism disorders, ALS.

Abbreviations:

FUS - fused in sarcoma, SDS - sodium dodecyl sulfate, TDP-43 - TAR DNA-binding protein 43, TOROID - TORC1 organized in inhibited domain.

INTRODUCTION

Certain proteins and peptides have been shown to be associated with disease when they form amyloid (or amyloid-like) oligomers or fibers. Amyloids are ordered protein aggregates characterized by a cross- β sheet structure that binds to thioflavin T [1]. Such proteins include: A β , α -synuclein, TDP-43 (TAR DNA-binding protein 43), FUS (fused in sarcoma), Huntingtin, and p53 which each form aggregates associated, respectively, with Alzheimer's, Parkinson's, amyotrophic lateral sclerosis (ALS)/ frontotemporal degeneration (FTD), Huntington's, and cancer [2-4]. Many of these proteins can also form liquid-like

droplets through liquid-liquid phase separation in the cytoplasm. These droplets can be dissolved by hexanediol, exhibit dynamic properties, and can convert into amyloid fibrils [5].

In most cases it is unclear which aggregate form is toxic. Indeed, the very structural nature of TDP-43 aggregates, whether found in patients, or formed *in vitro*, remains a subject of debate [6]. Some studies suggest that the low-complexity C-terminal domain of TDP-43 forms amyloid *in vitro* [7], while others report that neither *in vitro*-formed nor neuron-based TDP-43 aggregates exhibit amyloid properties [6, 8]. Although

TDP-43 aggregates are linked to disease, it is unclear whether they contribute to disease pathology or are merely a consequence of it.

Expression of TDP-43 in yeast causes toxicity [9] and a dramatic elongation of cell shape [10]. Mutations in TDP-43 which either increase or decrease its toxicity in yeast, hint that amyloid aggregates may actually have a protective role. Toxicity-enhancing intragenic mutations reduced TDP-43 hydrophobicity, while toxicity-reducing mutations increased hydrophobicity and encouraged larger TDP-43 aggregates in the cytoplasm [11]. However we found that expression of wild-type, non-toxic and toxicity-enhancing TDP-43 protein in yeast formed aggregates that were dissolved by hexanediol and were not stained with thioflavin T [10]. This indicates that all TDP-43 forms liquid-like droplets and not amyloid in yeast.

Expression of FUS in yeast is also toxic. However, unlike TDP-43, FUS aggregates stain with thioflavin T and do not disappear when cells are treated with hexanediol [10, 12-14].

Extragenic mutations also affect toxicity when TDP-43 is expressed in yeast [9, 15-20]. The mechanism by which TDP-43 causes toxicity remains unknown. However, we found that expression of wild-type TDP-43 in yeast reduces autophagy and TOROID (TORC1 organized in inhibited domain) formation. Extragenic and intragenic mutations which alleviate TDP-43 toxicity, reverse this effect [10, 20]. TOROIDs are large, helical structures of TORC1 that form near the vacuole and are associated with reduced autophagy inhibition.

Yeast prions also form amyloid. [*PSI*⁺] is the prion form of the translational release factor, SUP35. We showed that the *de novo* appearance of [*PSI*⁺] is dramatically enhanced by the presence of another yeast prion, [*PIN*⁺] (the prion form of RNQ1). Both the [*PSI*⁺] and [*PIN*⁺] prions can form different heritable amyloid shapes with distinct characteristics, called prion strains. Some [*PIN*⁺] strains destabilize [*PSI*⁺] strains and different [*PIN*⁺] strains preferentially promote the appearance of different [*PSI*⁺] strains. Other heterologous amyloid aggregates can also facilitate the *de novo* appearance of [*PSI*⁺] [21-27].

This type of interaction also occurs in mammalian cells. Aggregates of α -synuclein facilitate fibrillization of tau [28], and A β polymerization is promoted by misfolded type-2 diabetes islet amyloid polypeptide [29, 30]. This suggests that cross-seeding is a risk factor for disease.

Recently individual amino acids, and non-proteinaceous metabolites including adenine have also been shown to form amyloid-like fibers that bind thioflavin T and are toxic. Since inborn errors of metabolism disorders lead to accumulation of these fibers and cause neurological symptoms a "generic amyloid hypothesis" has been proposed to include both protein misfolding diseases and inborn errors of metabolism diseases [31-33].

Since these diseases are associated with an increased frequency of neurodegeneration and cancer, it is possible that the metabolite fibers serve as scaffolds upon which pathological protein aggregation can initiate [34].

A model for adenine self-assembly in living yeast was established by deleting two enzymes in the adenine salvage pathway: *APT1* (encoding adenine phosphoribosyltransferase) and *AAH1* (encoding adenosine deaminase). This double deletion causes a dramatic increase in the level of intracellular adenine which increases further when cells are grown in the presence of adenine. Furthermore, the increased intracellular adenine is amyloid-like and associated with growth inhibition [32].

Here, we use this yeast model to show that $apt1\Delta$ aah1 Δ double deletions alter the properties of human TDP-43 expressed in yeast.

RESULTS

Examining the toxicity of TDP-43 in yeast in the presence of $apt1\Delta$ $aah1\Delta$

As reported previously when TDP-43-YFP is expressed in yeast on galactose it forms foci, reduces growth rate, and causes an elongation of cell shape (Fig. 1A, B) [9, 35]. The double $apt1\Delta$ $aah1\Delta$ deletion ($\Delta\Delta$) significantly reduces this toxicity, resulting in a growth rate in between that seen with and without TDP-43 in wild-type cells (Fig. 1A). The $\Delta\Delta$ mutant also restores cells to their normal shape and causes a significant reduction in the number of cells with a multiple vs single TDP-43-YFP foci per cell (Fig. 1B, see also Fig. 4A).

A reduction in TDP-43 toxicity is observed with or without the addition of adenine to the media (**Fig. 1A**) and this is not caused by a reduction in TDP-43 expression (**Fig. 1C**). Addition of adenine doesn't affect the growth rate of wild-type cells but as reported previously [32] it reduces the growth rate of cells bearing the $apt1\Delta$ $aah1\Delta$ double deletion (**Fig. 1A**). The double deletion was specific for TDP-43, it didn't alter the toxicity of FUS (**Fig. 1A**).

Examining the effect of apt1\(\Delta\) aah1\(\Delta\) on inhibition of autophagy and TOROID formation caused by TDP-43 expression

The expression of wild-type TDP-43 in yeast reduces autophagy relative to the vector control [20]. As in our previous papers, we measured autophagy by using immunoblotting to examine the breakdown of GFP-ATG8 (Green Fluorescent Protein fused to autophagy-related protein 8) releasing free GFP (Fig. 2A) and by examining the cellular location of GFP in cells expressing GFP-ATG8 (Fig. 2B) [10, 20]. We previously found that modifiers (mutations in TIP41 or PBP1) that reduce toxicity of TDP-43 also reduce TDP-43's inhibition of autophagy [10, 20]. Similarly, our current results using both immunoblotting and cellular location measures of autophagy show that the level of autophagy is not altered by $apt1\Delta$ $aah1\Delta$ in the absence of TDP-43. However, both methods show that the presence of $apt1\Delta$ $aah1\Delta$ prevented overexpression of TDP-43 from inhibiting autophagy (Fig. 2A, B).

Previously described modifiers that reduce TDP-43's inhibition of autophagy were also found to lessen TDP-43's inhibition of TOROID formation, measured by the appearance of TOR1-GFP foci [10]. Likewise, we find that $apt1\Delta$ $aah1\Delta$ partially restores TOROID formation in cells expressing TDP-43 (Fig. 3).





FIGURE 1 ● The aah1∆ apt1∆ deletions alleviate TDP-43 but not FUS toxicity. (A) The double aah1∆ apt1∆ deletion alleviated toxicity associated with expression of TDP-43. TDP-43-YFP or FUS-YFP were expressed from the GAL promoter on CEN plasmids (YCpGAL-TDP43-YFP, and YCpGAL-FUS-YFP) in wild-type BY4741 (WT) or an isogenic double aah1∆ apt1∆ deletion strain (∆∆). Normalized transformants were serially diluted, spotted on plates (upper) or grown in liquid (lower). Cells were grown in plasmid selective media with glucose (non-inducing) or galactose (inducing YFP, TDP-43-YFP) as indicated. YFP-expressing cells were used as controls (YCpGAL-EYFP). No relief of FUS toxicity was observed in the aah1∆ apt1∆ strain compared to the wild type. (B) The double aah1∆ apt1∆ apt1A apt1∆ apt1A apt1∆ apt1A apt1∆ apt1A apt1∆ apt1A ap






FIGURE 2 • The aah1Δ apt1Δ double deletion reverses the inhibition of autophagy caused by overexpression TDP-43. (A) Autophagy measured by Western blots. Autophagy measured by the breakdown of GFP-ATG8 is shown on Western blots. BY4741 (WT) and three independently made isogenic double deletion strains (ΔΔ) were transformed with pGAL-TDP43-L and pCUP1-GFP-ATG8-U and grown on 2% galactose plates with 1% raffinose, the required amino acids methionine and histidine, and 50 μM copper sulfate for 16 hours at 30°C before being harvested for Western blotting. One representative blot is shown on the top left. The bar chart shows data from three independent double deletion strains repeated three times each and from a wild-type control. Also included as a control is a gel showing the breakdown of GFP-ATG8 in cells with the TDP-43 modifiers tip41Δ and pbp1Δ (upper right). As shown previously [20] these modifiers prevented TDP-43 from reducing autophagy. (B) Autophagy measured microscopically. Double transformants in BY4741 (WT) and isogenic double deletion strains (ΔΔ) shown in (A) were assayed for autophagy by determining the cellular location of GFP-ATG8 microscopically. Autophagy was measured as the fraction of cells with either no GFP-ATG8 fluorescence or with fluorescence only in the vacuole over total live cells. There was no significant difference in autophagy without TDP-43 expression (vec, vector) in the wild-type (WT) and double deletion strains (ΔΔ). Error bars represent the SEMs calculated from the average of three independent transformants by examining 250-550 cells per transformant. ** indicates p <0.01 in a paired two-tailed t-test.





FIGURE 3 ● The aah1∆ apt1∆ double deletion reduces the inhibition of TOROID formation caused by TDP-43 overexpression. Shown are fluorescent images of endogenously tagged TOR1 (GFP-TOR1) BY4741 cells with $(\Delta\Delta)$ or without (WT) the double aah1∆ apt1∆ deletion. Cells were transformed with untagged TDP-43 expressed under the GAL promoter in YCpGAL-TDP43-U (TDP-43) or empty vector YCp-GAL-U (v), grown on plasmid selective galactose media for 2 days, examined with a FITC filter and photographed (top). Scale bar is 10 µm. The percentage of cells with a GFP-TOR1 dot (TOROID) among live cells expressing TDP-43 or empty vector was counted after 0.5% trypan blue staining to exclude dead cells. There was no significant difference (ns) in TOROID formation between with (TDP-43) or without (V) TDP-43 expression in the double deletion strain. Live cells with GFP-TOR1 cytoplasmic foci were averaged from 3 independent transformants by examining about 500 cells per transformant. Error bars are SEMs from three independent transformants. Asterisks (***) indicate p < 0.001 in paired two-tailed t-tests, ns indicates no significant difference.



Examining the effect of $apt1\Delta$ aah1 Δ on the nature of TDP-43 foci


The frequency of TDP-43-YFP foci was higher (230 foci per 100 cells) in a wild-type vs. its isogenic $apt1\Delta$ $aah1\Delta$ derivative (95 foci per 100 cells) (Figs. 4A, C). In wild-type strains TDP-43-YFP usually forms one large irregularly shaped focus as well as multiple small foci. In these cells no foci are detected with thioflavin T staining. In the $apt1\Delta$ $aah1\Delta$ derivative there were seldom any small foci and the larger foci present were more punctate and slightly smaller than the large foci in wild-type cells (Figs. 1B and 4A). Surprisingly, many (~30%) of the TDP-43-YFP foci in the $apt1\Delta$ $aah1\Delta$ strain also stained with thioflavin T (Fig. 4A, C left). Although these thioflavin T+ TDP-43-YFP foci are not as bright as those seen for FUS-YFP foci, they are clearly visible. Also, while most (75%) of the thioflavin T foci that appear in the $apt1\Delta$ $aah1\Delta$ cells expressing TDP-43-YFP are also visible in the

YFP channel, about 25% are not. Indeed, a similar frequency of thioflavin T foci was also seen in $apt1\Delta$ $aah1\Delta$ cells not expressing TDP-43 (Fig. 4B, C right). These are likely amyloid adenine foci as previously described in $apt1\Delta$ $aah1\Delta$ cells [32]. Essentially no thioflavin T foci were seen in wild-type cells lacking TDP-43 and FUS (Fig. 4B, C right)

Further evidence that TDP-43 aggregates become amyloid in the $apt1\Delta$ $aah1\Delta$ strain is our finding that TDP-43 aggregates are resistant to boiling in the presence of SDS (Sodium Dodecyl Sulfate) in the $apt1\Delta$ $aah1\Delta$ but not wild-type strain (Fig. 4D). We used a filter trap assay that captures protein aggregates on a PVDF (polyvinylidene difluoride) membrane, allowing detection of SDS-resistant protein aggregates. TDP-43 aggregates formed in the $apt1\Delta$ $aah1\Delta$ strain, but not the wild-type strain, were retained on the membrane indicating increased SDS-resistant aggregation. Ponceau-S staining (right

panel) confirms total protein loading. These results suggest that the $\Delta\Delta$ stabilizes TDP-43-YFP aggregates, rendering them less susceptible to SDS solubilization which is characteristic of amyloids.

While the $apt1\Delta$ $aah1\Delta$ double deletion makes TDP-43-YFP more amyloid-like, it also reduces the liquid -like droplet nature of the TDP-43-YFP foci. This was evident because in the $apt1\Delta$ $aah1\Delta$ strain, cells with TDP-43-YFP foci retained foci following







FIGURE 5 ● The double aah1∆ apt1∆ deletion strain makes TDP-43 aggregates less liquid-like. Isogenic wild-type (WT) and aah1∆ apt1∆ deletion strains transformed with plasmid expressing YFP (YFP vector), TDP-43-YFP or FUS-YFP were grown overnight in plasmid selective galactose media lacking adenine. Their YFP fluorescence was examined prior to (No Hex) and following treatment with 10% 1,6-hexanadiol (Hex) for 5 minutes that dissolves liquid-like aggregates. Three transformants each were tested and gave similar results. (A) Hexanadiol doesn't dissolve all the TDP-43-YFP foci in the double aah1∆ apt1∆ deletion cells. Fluorescent pictures of cells under the microscope were taken with 40ms exposure, bright field images are shown to the right. Scale bar is 10 μm. (B) Quantification of foci in (A). ** indicates p <0.001 in a paired two-tailed t-test. The absence of stars indicates no statistical difference. (C) Hexanadiol doesn't dissolve foci that stain with thioflavin T in the aah1∆ apt1∆ strain. TDP-43-YFP and thioflavin T foci presence and overlap were quantified before and after treatment with hexanadiol. In ∆∆ cells transformed with YCpGAL-TDP43-YFP.U the number of YFP fluorescent foci (YFP*) per 100 cells that do (ThT*) or do not (ThT*) stain with thioflavin T are shown before and after treatment with hexanadiol. (D) ∆∆ cells not transformed with TDP-43-YFP, thioflavin T foci (YFP ThT*) before and after cells were treated with hexanadiol were counted.






FIGURE 6 FRAP analysis of TDP-43-YFP foci in wild-type and $aah1\Delta$ apt1 Δ deletion strains. BY4741 (WT) and double deletion ($\Delta\Delta$) strains were transformed with pGAL-TDP43-YFP-U and grown in 2% galactose media with 1% raffinose to induce TDP-43-YFP expression. FRAP (fluorescence recovery after photobleaching) was performed on individual TDP-43-YFP foci to assess their dynamic behavior. Top: Representative images of FRAP. For each strain, selected foci (blue circles) were photobleached, and fluorescence recovery was monitored over time. Dotted white lines outline the cell boundary. WT cells display visible fluorescence recovery after bleaching, whereas $\Delta\Delta$ cells show minimal to no recovery, indicating reduced mobility of molecules in TDP-43-YFP foci. Bottom: Quantification of normalized fluorescence intensity over time for individual foci (WT in blue, $\Delta\Delta$ in red). Each dot represents a single time point from a single focus (n = 9 for the WT strain; n=11 for the $\Delta\Delta$ strain). Solid lines represent the average fluorescence recovery curves for each strain (WT: blue line, $\Delta\Delta$: red line), serving as representative traces. Similar data was obtained on a different day when 11 foci in WT cells and 6 foci in $\Delta\Delta$ cells were examined (see supplementary data).

hexanediol treatment (Fig. 5A, B). In contrast, in wild-type cells TDP-43-YFP foci were all dissolved by hexanediol, indicating that they are liquid-like droplets rather than amyloid [10]. FUS-YFP foci were used as controls because they are amyloid. These foci stain with thioflavin T and are not dissolved by hexanediol [10]. Furthermore, when $apt1\Delta$ $aah1\Delta$ cells with TDP-43-YFP foci were treated with hexanediol, 90% of the remaining TDP-43-YFP foci stained with thioflavin T (Fig. 5C). This is consistent with the idea that hexanediol dissolves the liquid-like foci leaving amyloid foci intact. Likewise, hexanediol did not reduce the frequency of thioflavin T foci stained in $apt1\Delta$ $aah1\Delta$ cells not expressing TDP-43-YFP (Fig. 5D) supporting the assumption that these foci are amyloid.

Finally, fluorescence recovery after photobleaching (FRAP) showed that TDP-43-YFP foci formed in wild-type cells recovered much more efficiently than those in $apt1\Delta$ $aah1\Delta$ cells (Fig. 6 and Supplementary data). Wild-type foci gradually recovered, indicating dynamic and mobile assemblies, while foci in $\Delta\Delta$ remained mostly immobile, suggesting they are amyloid.

DISCUSSION

Previous studies have shown that the ability of amyloids to influence the aggregation of heterologous proteins, either promoting or inhibiting amyloid formation and by altering the type (strain) of amyloid promoted [21-27]. In this study, we aimed to determine whether adenine fibers could affect the aggregation and toxicity of TDP-43 in yeast.

The results indicate that the accumulation of adenine, and the formation of adenine amyloid-like fibers, significantly affects the aggregation properties and toxicity of TDP-43 in yeast. The double deletion of APT1 and AAH1, previously shown [32] to cause the accumulation of adenine amyloid-like fibers, reduces the toxicity of TDP-43 and the ability of TDP-43 to elongate cells. This occurs without lowering the levels of TDP-43 protein in the cell. Interestingly, these effects are not further enhanced by increasing adenine levels, which is surprising given that elevated adenine increases amyloid-like adenine fiber formation [32]. This lack of additional effect may be due to adenine itself being toxic at higher concentrations in the double deletion strain, thus masking any beneficial impact on TDP-43 toxicity. Like other modifiers of TDP-43 toxicity [10, 20], the double deletion reduces the inhibition of autophagy and TO-ROID formation caused by expression of TDP-43. This reduction occurs even though the double deletion itself does not affect autophagy or TOROID formation in the absence of TDP-

The TDP-43 foci formed in the double deletion strain differ from those in wild-type cells. All 20 TDP-43 foci tested for FRAP in the double deletion showed reduced mobility compared to the 17 TDP-43 foci tested in wild-type cells. Furthermore, while all TDP-43 foci in wild-type cells are dissolved by hexanediol, 30% of the TDP-43 foci in the double deletion are resistant to hexanediol and 90% of these stain with thioflavin T. Therefore, TDP-43 foci in the double deletion are less-liquid like and more

amyloid like. These amyloid-like foci appear to be less toxic and less disruptive to autophagy and TOROID formation than the liquid-like TDP-43 foci formed in wild-type cells. Importantly, the data indicate that liquid-like TDP-43 foci are the toxic species. The FRAP results indicate that all of the TDP-43 foci in the double deletion strain have become more amyloid like even though they aren't all stained with thioflavin T and some can still be dissolved by hexanediol.

One possible explanation for these differences is cross-seeding between adenine fibers and TDP-43. Cross-seeding is a well-established phenomenon where aggregates of one amyloid protein can influence the aggregation of another. *In vitro* studies have shown that hnRNPA1 hydrogels can directly cross-seed the aggregation of FUS, another amyloid-forming protein [36]. It is plausible that a similar mechanism is at play here, where adenine fibers interact with TDP-43, altering its aggregation state and reducing its toxicity.

This hypothesis raises an interesting question: if adenine fibers are indeed interacting with TDP-43, why does the double deletion strain reduce TDP-43 toxicity even without added adenine? This could be explained by the fact that the double deletion induces a baseline level of intracellular adenine amyloid-like fiber, even without added adenine [32]. This low level of fibers might be sufficient to affect TDP-43 aggregation, so any additional adenine beyond this threshold might not further influence the properties of TDP-43 aggregates.

While the observed effects might be indirect, the ability of excess cellular adenine to influence TDP-43 aggregation properties supports the idea that amyloid-like adenine fibers can affect other cellular amyloids or aggregates. This suggests a broad role for metabolite-based amyloid structures in modulating the behavior of pathological protein aggregates in cells.

CONCLUSION

In summary, the paper shows that the double deletion of *APT1* and *AAH1* reduces TDP-43's toxicity and inhibition of autophagy and TOROID formation. At the same time, the double deletion makes TDP-43 foci more amyloid like as judged by reduced mobility measured with FRAP, an increase in thioflavin T staining, and reduced dissolution by hexanediol. Possibly cross-seeding TDP-43 with adenine fibers, results in the altered TDP-43 aggregate properties. These results open new avenues for exploring the role of metabolite-based amyloids in modulating protein aggregation and toxicity, with potential implications for understanding the broader landscape of protein misfolding diseases. Further studies will be required to determine whether these effects are mediated through direct interactions between adenine fibers and TDP-43.

MATERIAL AND METHODS Strains and plasmids

Strains used are shown in **Table 1**, plasmids in **Table 2**. To construct the $apt1\Delta$ $aah1\Delta$ strain, we began with BY4741 [37] containing apt1:: hphMX6 obtained from Matin Kupiac's collection via Dana Laor [32] and BY4741 aah1::KanMX6 from the

TABLE 1 • Strains.

Strains	Description	Reference
BY4741	MAT \mathbf{a} his3 Δ 1 leu2 Δ 0 met15 Δ 0 ura3 Δ 0	[38]
apt1∆	BY4741 apt1::hphMX6	[32]
aah1∆	BY4741 aah1::KanMX6	Open Biosystems (Huntsville, AL, USA)
apt1∆aah1∆	BY4741 apt1::hphMX6, aah1::KanMX6	This study

TABLE 2 Plasmids.

Short name, SWL laboratory plasmid #	Description	Reference
pSK108	pRS305PTOR1 (1000 bases)-GFP-TOR1 (426 N- terminal bases), LEU2	[39]
YCpGAL-EYFP, p2260	pAG416 Gal-ccdB-EYFP (URA3, CEN)	Addgene plasmid #14219, made by Aaron Gitler
YCpGAL-TDP43YFP, p2042	pRS416 Gal-TDP YCpGAL-TDP-43-YFP, (<i>URA3, CEN</i>)	Addgene plasmid #27447, deposited by Aaron Gitler
YCpGAL-FUS-YFP, p2043	pRS416 Gal-FUS-EYFP (<i>URA3, CEN</i>)	[14]
YCpGAL-U, p2129	pAG416 Gal-ccdB (URA3, CEN)	Addgene plasmid #14147, made by Aaron Gitler
YCpGAL-TDP43-U, p2665	pAG416 Gal-TDP-43 (URA3, CEN)	[10]
YCpGAL-L, p2245	pAG415 Gal-ccdB (<i>LEU2, CEN</i>)	Addgene plasmid #14145, made by Aaron Gitler
YCpGAL-TDP43-L, p2368	pAG415 Gal-TDP-43 (<i>LEU2, CEN</i>)	[10]
YCpCUP1-GFP-ATG8, p2571	pCUP1-GFP-ATG8 (<i>URA3, CEN</i>)	Addgene #49423, deposited by Daniel Klionsky

deletion library [38]. We transformed the BY4741 apt1::hphMX6 strain with a PCR-amplified aah1::KanMX6 fragment using upstream and downstream gene-specific 45mer primers. Cells were first grown on a YPD plate before being plated on YPD containing 200 µg /ml G418 to select for double deletion strains. These strains were further validated by growth on YPD containing 200 µg /ml hygromycin. The gene disruptions were confirmed with PCR.

To measure TOROID formation, we disrupted TOR1 while integrating GFP-TOR1 controlled by its native promoter into BY4741. Wild-type BY4741 or $apt1\Delta$ $aah1\Delta$ strains were transformed with SpeI-digested integrating pSK108 plasmid (LEU2) containing the TOR1 promoter and GFP tagged N-terminal region (kindly sent by Dr. Noda) [39] and selecting for transformants on leucine-less media. SpeI makes a unique cut in the N-terminal TOR1 region on the plasmid. The correct insertions were confirmed with PCR. Plasmid pSK108 is described in Table 2.

Scoring for growth

Standard yeast medium was used throughout [40]. To assess the growth of $apt1\Delta$ $aah1\Delta$ cells expressing plasmids, transformants were grown overnight on plasmid selective synthetic

glucose medium lacking adenine. Cells to be examined for growth on TDP-43 expressing galactose plates were then normalized to OD_{600} = 4, serially diluted in water 10X, spotted on synthetic medium plates made with 2% glucose or 2% galactose supplemented with required amino acids, yeast nitrogen base without amino acids, and 0 or 1 mg/L adenine, and incubated at 30°C for four days. Cells to be used for growth curves were normalized to OD_{600} = 0.2 in synthetic raffinose/galactose (SRafGal) medium lacking adenine. A total of 200 μ L of the diluted cultures was transferred into a 96-well plate and incubated at 30°C for 25 hours with continuous shaking. OD_{600} readings were recorded using a SpectraMax M5 (Molecular Devices, Sunnyvale, CA) microplate reader. The data presented are representative of experiments performed in triplicate.

Microscopy for YFP tagged proteins before and after 1,6 hexanediol treatment, and for thioflavin T-stained protein

A Nikon Eclipse E600 fluorescent microscope (Nikon, Tokyo, Japan) with 100×/1.23 NA or 60×/1.4 NA oil immersion objectives was used to observe YFP fluorescence with a YFP filter, with or without prior 1,6 hexanediol treatment. Cells were also observed in brightfield. Thioflavin T-stained fluorescent foci were observed using a CFP filter. Post-acquisition image pro-

cessing (brightness and contrast) was performed using Adobe Photoshop 2024 (San Jose, California), and all micrographs display a scale bar. Detailed methods have been described previously [10].

Scoring for autophagy by determination of GFP-ATG8 cleavage with western blots and microscopic fluorescence counting

BY4741 WT and its isogenic double apt1\(Delta \) aah1\(Delta \) deletion strain were doubly transformed with YCpGAL-TDP-43-L and YCpCUP1-GFP-ATG8. The transformants grown on plasmid selective glucose plates lacking adenine were normalized to 0.2 OD600 and spread on TDP-43 and GFP-ATG8 overexpressing plasmid selective galactose plates with 1% raffinose and 50 µM CuSO₄. Preparation of lysates and immunoblotting were as described previously [20]. α -GFP (1:5000, Roche); α -TDP-43 (1:3000; Proteintech Group); and α -PGK (yeast 3phosphoglycerate kinase, 1:10,000, Novex) were respectively used to compare the levels of uncleaved GFP-ATG8 and cleaved GFP, TDP-43, and PGK (yeast 3-phosphoglycerate kinase). The ratio of cleaved GFP to uncleaved GFP-ATG8 measures autophagy. The internal PGK control was used to compare the level of TDP-43 present in the wild-type (WT) vs. the double deletion strain $(\Delta\Delta)$.

Microscopic determination of the cellular location of GFP-ATG8 was also used to measure autophagy. Autophagy was calculated as the fraction of cells with either no fluorescence or with fluorescence only in the vacuole over total live cells. Dead cells were detected with trypan blue staining seen in brightfield. Microscopic determination of the location of the GFP-ATG8 fluorescence was as previously reported [20].

Measuring TOROID formation

TOROID formation was measured as described previously [20].

Filter trap assay

The filter trap assay was done as described previously [41, 42]. Briefly, yeast cell lysates expressing TDP-43-YFP were prepared in buffer B (50 mM Tris-HCl, pH 7.0, 150 mM NaCl) and heated at 95°C for 7 minutes in the presence or absence of SDS (0%, 2%, or 4%). Samples were then subjected to vacuum filtration through a PVDF membrane using a 96-well dot blot apparatus (Bio-Rad Laboratories, Hercules, CA). After filtration, membranes were washed twice with the respective SDS concentration used in sample preparation and blocked in 2% Tropix O-Block (Applied Biosystems, Bedford, MA) in blocking buffer (100 mM Tris-HCl, pH 7.4, 150 mM NaCl) for 1 hour. Membranes were incubated with primary antibodies against TDP-43 at a 1:2000 dilution for 1 hour. After washing twice with blocking buffer, membranes were incubated with APconjugated secondary antibody for 1 hour. Following additional washes, the membranes were developed using the Tropix CDP-Star System (Applied Biosystems, Bedford, MA). The

membrane was then stripped and stained with Ponceau-S to quantify total protein present.

Fluorescence recovery after photobleaching (FRAP)

FRAP assays were performed as previously described [11], with minor modifications. Briefly, yeast cells expressing TDP-43-YFP in either wild-type or double deletion ($\Delta\Delta$) strains were cultured overnight in selective galactose medium supplemented with 1% raffinose to induce protein expression. Cells were immobilized onto microscopy slides pre-coated with 1 mg/mL concanavalin A (Sigma-Aldrich, St. Louis and Burlington, MA) to promote cell adhesion. FRAP experiments were conducted using a Leica Stellaris 8 confocal microscope (Leica Microsystems, Germany) equipped with an 86× waterimmersion objective. Image acquisition was performed at a resolution of 512 × 512 pixels. Targeted photobleaching of defined TDP-43-YFP foci was performed using a white laser set at 513 nm and 80% laser intensity. For each sample, approximately 120 frames were acquired including 5 pre-bleach frames at 1.3-second intervals, 15 bleach frames at 0.3-second intervals, and subsequent recovery imaging for up to 250 seconds at 1.3-second intervals. Fluorescence intensity within the region of interest (ROI) was measured using LAS X software (Leica Microsystems, Germany), normalized to the pre-bleach signal, and recovery curves were analyzed as previously described [43].

ACKNOWLEDGEMENTS

We thank Robbie Joséph Loewith, Daniel J. Klionsky, Aaron Gitler, Susan Lindquist, Martin Kupiac, Dana Laor, and Ehud Gazit for the gifts of plasmids and strains, and Irina Derkatch for helpful suggestions. This work was funded by a National Institutes of Health MIRA grant (1R35GM136229-04) awarded to S.W.L. and was made possible by a grant from the National Institute of General Medical Sciences (P20GM130459) from the National Institutes of Health.

SUPPLEMENTAL MATERIAL

All supplemental data for this article are available online at www.microbialcell.com.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

COPYRIGHT

© 2025 Park et al. This is an open-access article released under the terms of the Creative Commons Attribution (CC BY) license, which allows the unrestricted use, distribution, and reproduction in any medium, provided the original author and source are acknowledged.

Please cite this article as: Sangeun Park, Sei-Kyoung Park, Peter Blair and Susan W. Liebman (2025). An adenine model of inborn metabolism errors alters TDP-43 aggregation and reduces its toxicity in yeast revealing insights into protein misfolding diseases. Microbial Cell 12: 119-131. doi: 10.15698/mic2025.05.850

REFERENCES

- 1. Greenwald J, Riek R (2010). Biology of amyloid: structure, function, and regulation. Structure 18: 1244-1260. doi: 10.1016/j.str.2010.08.009
- 2. Frost B, Diamond MI (2010). Prion-like mechanisms in neurodegenerative diseases. Nat Rev Neurosci 11: 155-159. doi: 10.1038/nrn2786
- 3. Park SK, Park S, Pentek C, Liebman SW (2021). Tumor suppressor protein p53 expressed in yeast can remain diffuse, form a prion, or form unstable liquid-like droplets. iScience 24: 102000. doi: 10.1016/j.isci.2020.102000
- 4. Silva JL, De Moura Gallo CV, Costa DC, Rangel LP (2014). Prion-like aggregation of mutant p53 in cancer. Trends Biochem Sci 39: 260-267. doi: 10.1016/jtibs.2014.04.001
- 5. Heinrich S, Hondele M (2022). Probing Liquid-Liquid Phase Separation of RNA-Binding Proteins In Vitro and In Vivo. **Methods Mol Biol** 2537: 307-333. doi: $10.1007/978-1-0716-2521-7_18$
- 6. Capitini C, Fani G, Vivoli Vega M, Penco A, Canale C, Cabrita LD, Calamai M, Christodoulou J, Relini A, Chiti F (2021). Full-length TDP-43 and its C-terminal domain form filaments in vitro having non-amyloid properties. Amyloid 28: 56-65. doi: 10.1080/13506129.2020.1826425
- 7. Shenoy J, Lends A, Berbon M, Bilal M, El Mammeri N, Bertoni M, Saad A, Morvan E, Grelard A, Lecomte S, et al (2023). Structural polymorphism of the low-complexity C-terminal domain of TDP-43 amyloid aggregates revealed by solid-state NMR. Front Mol Biosci 10: 1148302. doi: 10.3389/fmolb.2023.1148302
- 8. Cascella R, Banchelli M, Abolghasem Ghadami S, Ami D, Gagliani MC, Bigi A, Staderini T, Tampellini D, Cortese K, Cecchi C, et al (2023). An in situ and in vitro investigation of cytoplasmic TDP-43 inclusions reveals the absence of a clear amyloid signature. Ann Med 55: 72-88. doi: 10.1080/07853890.2022.2148734
- 9. Armakola M, Hart MP, Gitler AD (2011). TDP-43 toxicity in yeast. Methods 53: 238-245. doi: 10.1016/j.ymeth.2010.11.006
- 10. Park S, Park SK, Liebman SW (2024). Expression of Wild-Type and Mutant Human TDP-43 in Yeast Inhibits TOROID (TORC1 Organized in Inhibited Domain) Formation and Autophagy Proportionally to the Levels of TDP-43 Toxicity. Int J Mol Sci 25(11): 6258. doi: 10.3390/ijms25116258
- 11. Bolognesi B, Faure AJ, Seuma M, Schmiedel JM, Tartaglia GG, Lehner B (2019). The mutational landscape of a prion-like domain. Nat Commun 10: 4162. doi: 10.1038/s41467-019-12101-z
- 12. Ju S, Tardiff DF, Han H, Divya K, Zhong Q, Maquat LE, Bosco DA, Hayward LJ, Brown RH, Jr., Lindquist S, et al (2011). A yeast model of FUS/TLS-dependent cytotoxicity. PLoS Biol 9: e1001052. doi: 10.1371/journal.pbio.1001052
- 13. Fushimi K, Long C, Jayaram N, Chen X, Li L, Wu JY (2011). Expression of human FUS/TLS in yeast leads to protein aggregation and cytotoxicity, recapitulating key features of FUS proteinopathy. Protein Cell 2: 141-149. doi: 10.1007/s13238-011-1014-5
- 14. Park S, Park SK, Watanabe N, Hashimoto T, Iwatsubo T, Shelkovnikova TA, Liebman SW (2019). Calcium-responsive transactivator (CREST) toxicity is rescued by loss of PBP1/ATXN2 function in a novel yeast proteinopathy model and in transgenic flies. PLoS Genet 15: e1008308. doi: 10.1371/journal.pgen.1008308
- 15. Johnson BS, McCaffery JM, Lindquist S, Gitler AD (2008). A yeast TDP-43 proteinopathy model: Exploring the molecular determinants of TDP-43 aggregation and cellular toxicity. **Proc Natl Acad Sci U S A** 105: 6439-6444. doi: 10.1073/pnas.0802082105
- 16. Figley MD, Gitler AD (2013). Yeast genetic screen reveals novel therapeutic strategy for ALS. Rare Dis 1: e24420. doi: 10.4161/rdis.24420

- 17. Kim JH, Rahman MH, Park D, Jo M, Kim HJ, Suk K (2021). Identification of Genetic Modifiers of TDP-43: Inflammatory Activation of Astrocytes for Neuroinflammation. Cells 10(3): 676. doi: 10.3390/cells 10030676
- 18. Park SK, Arslan F, Kanneganti V, Barmada SJ, Purushothaman P, Verma SC, Liebman SW (2018). Overexpression of a conserved HSP40 chaperone reduces toxicity of several neurodegenerative disease proteins. Prion 12: 16-22. doi: 10.1080/19336896.2017.1423185
- 19. Peggion C, Massimino ML, Stella R, Bortolotto R, Agostini J, Maldi A, Sartori G, Tonello F, Bertoli A, Lopreiato R (2021). Nucleolin Rescues TDP-43 Toxicity in Yeast and Human Cell Models. Front Cell Neurosci 15: 625665. doi: 10.3389/fncel.2021.625665
- 20. Park SK, Park S, Liebman SW (2022). TDP-43 Toxicity in Yeast Is Associated with a Reduction in Autophagy, and Deletions of TIP41 and PBP1 Counteract These Effects. Viruses 14(10): 2264. doi: 10.3390/v14102264
- 21. Derkatch IL, Bradley ME, Hong JY, Liebman SW (2001). Prions affect the appearance of other prions: the story of [PIN(+)]. Cell 106: 171-182. doi: 10.1016/s0092-8674(01)00427-5
- 22. Derkatch IL, Chernoff YO, Kushnirov VV, Inge-Vechtomov SG, Liebman SW (1996). Genesis and variability of [PSI] prion factors in Saccharomyces cerevisiae. Genetics 144: 1375-1386. doi: 10.1093/genetics/144.4.1375
- 23. Derkatch IL, Liebman SW (2007). Prion-prion interactions. **Prion 1:** 161-169. doi: 10.4161/pri.1.3.4837
- 24. Derkatch IL, Uptain SM, Outeiro TF, Krishnan R, Lindquist SL, Liebman SW (2004). Effects of Q/N-rich, polyQ, and non-polyQ amyloids on the de novo formation of the [PSI+] prion in yeast and aggregation of Sup35 in vitro.

 Proc Natl Acad Sci U S A 101: 12934-12939. doi: 10.1073/pnas.0404968101
- 25. Vitrenko YA, Gracheva EO, Richmond JE, Liebman SW (2007). Visualization of aggregation of the Rnq1 prion domain and cross-seeding interactions with Sup35NM. J Biol Chem 282: 1779-1787. doi: 10.1074/jbc.M609269200
- 26. Sharma J, Liebman SW (2013). Exploring the basis of [PIN(+)] variant differences in [PSI(+)] induction. J Mol Biol 425: 3046-3059. doi: 10.1016/j,jmb.2013.06.006
- 27. Sharma J, Liebman SW (2013). Variant-specific prion interactions: Complicating factors. Cell Logist 3: e25698. doi: 10.4161/cl.25698
- 28. Guo JL, Covell DJ, Daniels JP, Iba M, Stieber A, Zhang B, Riddle DM, Kwong LK, Xu Y, Trojanowski JQ, Lee VM (2013). Distinct alpha-synuclein strains differentially promote tau inclusions in neurons. **Cell** 154: 103-117. doi: 10.1016/j.cell.2013.05.057
- 29. Moreno-Gonzalez I, Edwards III G, Salvadores N, Shahnawaz M, Diaz-Espinoza R, Soto C (2017). Molecular interaction between type 2 diabetes and Alzheimer's disease through cross-seeding of protein misfolding. Mol Psychiatry 22: 1327-1334. doi: 10.1038/mp.2016.230
- 30. Akter K, Lanza EA, Martin SA, Myronyuk N, Rua M, Raffa RB (2011). Diabetes mellitus and Alzheimer's disease: shared pathology and treatment? Br J Clin Pharmacol 71: 365-376. doi: 10.1111/j.1365-2125.2010.03830.x
- 31. Gazit E (2016). Metabolite amyloids: a new paradigm for inborn error of metabolism disorders. J Inherit Metab Dis 39: 483-488. doi: 10.1007/s10545-016-9946-9
- 32. Laor D, Sade D, Shaham-Niv S, Zaguri D, Gartner M, Basavalingappa V, Raveh A, Pichinuk E, Engei H, Lwasaki K, et al (2019). Fibril formation and therapeutic targeting of amyloid-like structures in a yeast model of adenine accumulation. Nat Commun 10(1):62. doi: 10.1038/s41467-018-07966-5
- 33. Rencus-Lazar S, DeRowe Y, Adsi H, Gazit E, Laor D (2019). Yeast Models for the Study of Amyloid-Associated Disorders and Development of Future Therapy. Front Mol Biosci 6: 15. doi: 10.3389/fmolb.2019.00015

- 34. Sade D, Shaham-Niv S, Arnon ZA, Tavassoly O, Gazit E (2018). Seeding of proteins into amyloid structures by metabolite assemblies may clarify certain unexplained epidemiological associations. Open Biol 8(1): 170229. doi: 10.1098/rsob.170229
- 35. Park SK, Hong JY, Arslan F, Kanneganti V, Patel B, Tietsort A, Tank EMH, Li X, Barmada SJ, Liebman SW (2017). Overexpression of the essential Sis1 chaperone reduces TDP-43 effects on toxicity and proteolysis. PLoS Genet 13: e1006805. doi: 10.1371/journal.pgen.1006805
- 36. Kato M, Han TW, Xie S, Shi K, Du X, Wu LC, Mirzaei H, Goldsmith EJ, Longgood J, Pei J, et al (2012). Cell-free formation of RNA granules: low complexity sequence domains form dynamic fibers within hydrogels. Cell 149: 753-767. doi: 10.1016/j.cell.2012.04.017
- 37. Brachmann CB, Davies A, Cost GJ, Caputo E, Li J, Hieter P, Boeke JD (1998). Designer deletion strains derived from Saccharomyces cerevisiae S288C: a useful set of strains and plasmids for PCR-mediated gene disruption and other applications. Yeast 14: 115-132. doi: 10.1002/(SICI)1097-0061(19980130)14:2<115::AID-YEA204>3.0.CO;2-2
- 38. Winzeler EA, Shoemaker DD, Astromoff A, Liang H, Anderson K, Andre B, Bangham R, Benito R, Boeke JD, Bussey H, et al (1999). Functional charac-

- terization of the S. cerevisiae genome by gene deletion and parallel analysis. **Science** 285: 901-906. doi: 10.1126/science.285.5429.901
- 39. Kira S, Tabata K, Shirahama-Noda K, Nozoe A, Yoshimori T, Noda T (2014). Reciprocal conversion of Gtr1 and Gtr2 nucleotide-binding states by Npr2-Npr3 inactivates TORC1 and induces autophagy. Autophagy 10: 1565-1578.doi: 10.4161/auto.29397
- 40. Sherman F FG, Hicks JB (1986). Methods in Yeast Genetics. Plainview, Cold Spring Harbor Press, New York: Cold Spring Harbor Press.
- 41. Oullier T, Prigent A, Chapelet G, Neunlist M, Letournel F, Derkinderen P. (2020) Optimizing filter trap assay for the detection of aggregated alphasynuclein in brain samples. Free Neuropathol 1: 14. doi: 10.17879/freeneuropathology-2020-2749
- 42. Kuret J (2007). Detection and Quantification of Tau Aggregation Using a Membrane Filter Assay. Anal Biochem 373: 330-336. doi: 10.1016/j.ab.2007.09.015
- 43. Wu Y, Masision DC, Eisenberg E, Greene LE (2006) Application of photobleaching for measuring diffusion of prion proteins in cytosol of yeast cells. Methods 39: 43-49. doi: 10:1016/j.meth.2006